General Information
Drug ID
DR00225
Drug Name
Quercetin
Synonyms
2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,3',4,5,7-Pentahydroxyflavone; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; C.I. Natural yellow 10 & 13; CI Natural Yellow 10; CU-01000012502-3; Cyanidelonon 1522; Flavin meletin; KSC-10-126; KSC-23-76; KUC104418N; KUC107684N; Kvercetin; Kvercetin [Czech]; LIM-5662; LNS-5662; Meletin; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; QUE; Quercetin content; Quercetin dihydrate; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; T-Gelb bzw. grun 1; TNP00070; TNP00089; Xanthaurine
Drug Type
Small molecular drug
Indication Coronary artery disease [ICD11: BA6Z] Phase 3 [1]
Obesity [ICD11: 5B81] Phase 3 [1]
Therapeutic Class
Hypoglycemic Agents
Structure
3D MOL 2D MOL
Formula
C15H10O7
Canonical SMILES
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
InChI
InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
InChIKey
REFJWTPEDVJJIY-UHFFFAOYSA-N
CAS Number
CAS 117-39-5
Pharmaceutical Properties Molecular Weight 302.23 Topological Polar Surface Area 127
Heavy Atom Count 22 Rotatable Bond Count 1
Hydrogen Bond Donor Count 5 Hydrogen Bond Acceptor Count 7
XLogP
1.5
PubChem CID
5280343
PubChem SID
10318962 , 10318963 , 10589526 , 11108251 , 11111704 , 11111705 , 11111706 , 11113933 , 11120249 , 11120737 , 11121225 , 11121719 , 11122199 , 11335660 , 11360899 , 11362822 , 11362998 , 11365384 , 11365560 , 11367946 , 11368122 , 11370875 , 11370876 , 11371563 , 11373547 , 11374432 , 11376108 , 11376284 , 11387263 , 11401319 , 11446388 , 11455076 , 11455328 , 11461871 , 11466535 , 3157247 , 3679 , 5183365 , 596331 , 74741 , 7636346 , 7884117 , 7890165 , 8137945 , 8145679 , 8149624 , 820896 , 821326 , 841197 , 8616230
ChEBI ID
ChEBI:16243
TTD Drug ID
D0K8KX
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
FLVCR1 Transporter Info Feline leukemia virus subgroup C receptor-related protein 1 Substrate [3]
GLUT1 Transporter Info Glucose transporter type 1 Substrate [4]
MCT2 Transporter Info Monocarboxylate transporter 2 Substrate [5]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [6]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [7]
References
1 ClinicalTrials.gov (NCT03943459) Sirtuin-1 and Advanced Glycation End-products in Postmenopausal Women With Coronary Disease
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
3 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.1.28.1)
4 Oral Bioavailability and Disposition of Phytochemicals
5 Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
6 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
7 Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.